Tissue engineering and regenerative medicine in the AI era

Title : Tissue engineering and regenerative medicine in the AI era

Abstract:

Tissue Engineering and Regenerative Medicine in the AI Era represents a transformative convergence of biology, materials science, and digital intelligence. Artificial Intelligence (AI) is reshaping how we design, fabricate, and apply regenerative therapies, accelerating the path from bench to bedside with unprecedented precision and speed. In the AI era, tissue engineering and regenerative medicine are entering a new frontier where data-driven design, automation, and personalization enhance outcomes, reduce costs, and accelerate innovation. The synergy between biological systems and artificial intelligence holds enormous potential but it must be matched with robust ethics, regulatory adaptation, and cross-disciplinary collaboration.

Biography:

Dr. Vasiliki E. Kalodimou is the Assistant Professor as well as the former acting chair, at School of Medicine at the European University-Cyprus Ltd. Frankfurt Branch, Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO Maternity-Pediatric and Research Hospital in Athens, Greece, the Board/Committee on Research Ethics at the National Hellenic Research Foundation (Ε.Ι.Ε). Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine, clinical trials, medical tourism and Flow Cytometry. Also, is working in the area of human genetics & population genetics as well as cellular standards. In addition to collaboration with state universities and pharmaceutical companies on research projects (20), Kalodimou frequently publishes (55 & 14 books/bestseller) her findings. She has 2 patents.